Moreover, blocking IL-1β with a monoclonal antibody, canakinumab, has resulted in a lower rate of recurrent cardiovascular events, cardiovascular complications, and cardiovascular mortality in patients with MI [31]. Here, IL1B is linked to myocardial infarction.